The Legacy Hub Model Is Dead

Ankit Jain runs a company that is actively taking business from legacy specialty hubs, so treat the claim accordingly. But he said it in his own office, on camera, without hedging: the legacy hub model is dead, and the people running those hubs don’t realize they stopped competing with hubs a while ago. They’re competing with technology companies now, and the person who signs the contract has changed. I spent fifteen years inside that model. I pushed back where I could.What we got into04:22 — The 40% of patients prescribed a therapy requiring prior authorization who never get on it.21:49 — Blizzard season. Hire in September, train through December, buy about three weeks of work in January. Every year.27:18 — Infinitus audits 100% of calls. A traditional hub audits three to five percent.29:03 — Charging for outcomes instead of hours, and why the incentives under the old model were never aligned.35:11 — The buyer moved. It’s the commercial CIO now, and that CIO isn’t calling legacy hubs at all.39:00 — What a hub quoted to hand a manufacturer back its own patient data. Half a million to a million dollars.48:23 — Where the clinical escalation ladder stops and a human picks up.1:03:03 — An $1,800 copay that became $125 during a 25-minute walk to the pharmacy.Watch the video version on YouTube: https://www.youtube.com/watch?v=EBr_YCdK44AAnkit Jain is CEO and co-founder of Infinitus. I’m Ankur Jain, founder of Artha Consulting Lab, fifteen years in specialty pharmacy and market access across Takeda, Novartis, Merck and Pfizer.This is The Hub Brief. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit thehubbrief.substack.com